Dr. @Joshua_Reuss, now presenting "Biomarker Testing Fundamentals".

Molecular testing plays a critical role in all stages of non-small cell lung cancer.

Join us here: give.cancergrace.org/event/lung-c...

#TrueOrFalse

#LungCancer #NCSLC #cancerGRACE

Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases Dato-DXd demonstrated CNS PFS and ORR benefits vs docetaxel in patients with NSCLC with brain metastases.

Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases
@iaslc.bsky.social #WCLC25 #NCSLC #LCSM
www.onclive.com/view/dato-dx...

Tiragolumab Plus Atezolizumab Fails to Meet Survival End Points in Previously-Untreated, PD-L1–High NSCLC First-line tiragolumab plus atezolizumab did not improve PFS and OS vs atezolizumab alone in PD-L1–high, unresectable or metastatic NSCLC.

Tiragolumab Plus Atezolizumab Fails to Meet Survival End Points in Previously-Untreated, PD-L1–High NSCLC
@theaacr.bsky.social #AACR25 #NCSLC #LCSM
www.onclive.com/view/tiragol...

Optune Lua Granted CE Mark Approval in EU for Metastatic NSCLC A CE Mark has been granted to Optune Lua concurrent with immune checkpoint inhibitors or docetaxel for patients with metastatic non–small cell lung cancer.

Optune Lua Granted CE Mark Approval in EU for Metastatic NSCLC
#NCSLC #LCSM
www.onclive.com/view/optune-...

Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study Investigators found that the cancer-controlling effects of immune checkpoint inhibitors continue even after treatment is stopped due to immune-related adverse events in patients with advanced NSCLC.

Effects of Immunotherapy Can Last After Treatment Stops According to Dana-Farber Study
@danafarbernews.bsky.social #NCSLC #LungCancer
www.onclive.com/view/effects...

The #FDA approved ensartinib for ALK+ locally advanced or metastatic non-small cell lung cancer. #lcsm #NCSLC

www.targetedonc.com/view/fda-app...